Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.
Fiche publication
Date publication
novembre 2010
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr COUTANT Charles
Tous les auteurs :
Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-Figueroa LJ, Souchon E, Coutant C, Doimi FD, Ibrahim NK, Gong Y, Hortobagyi GN, Hess KR, Symmans WF, Pusztai L
Lien Pubmed
Résumé
We examined in a prospective, randomized, international clinical trial the performance of a previously defined 30-gene predictor (DLDA-30) of pathologic complete response (pCR) to preoperative weekly paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide (T/FAC) chemotherapy, and assessed if DLDA-30 also predicts increased sensitivity to FAC-only chemotherapy. We compared the pCR rates after T/FAC versus FACx6 preoperative chemotherapy. We also did an exploratory analysis to identify novel candidate genes that differentially predict response in the two treatment arms.
Mots clés
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Biomarkers, Pharmacological, analysis, Biomarkers, Tumor, analysis, Breast Neoplasms, diagnosis, Carcinoma, Ductal, Breast, diagnosis, Cyclophosphamide, administration & dosage, Doxorubicin, administration & dosage, Female, Fluorouracil, administration & dosage, Gene Expression Regulation, Neoplastic, drug effects, Humans, Middle Aged, Paclitaxel, administration & dosage, Predictive Value of Tests, Prognosis, Treatment Outcome
Référence
Clin. Cancer Res.. 2010 Nov;16(21):5351-61